<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03911193</url>
  </required_header>
  <id_info>
    <org_study_id>CABinMET</org_study_id>
    <nct_id>NCT03911193</nct_id>
  </id_info>
  <brief_title>CABozantinib in Non-Small Cell Lung Cancer (NSCLC) Patients With MET Deregulation</brief_title>
  <acronym>CABinMET</acronym>
  <official_title>Phase II Single Arm Study With CABozantinib in Non-Small Cell Lung Cancer Patients With MET Deregulation</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Fondazione Ricerca Traslazionale</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Fondazione Ricerca Traslazionale</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a multicenter, single arm, phase II study evaluating efficacy in terms of RR in a&#xD;
      cohort of NSCLC with MET amplification or MET exon 14 skipping mutation pre-treated or not&#xD;
      with MET inhibitors.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The study population will include NSCLC patients with MET amplification or MET exon 14&#xD;
      skipping mutation pre-treated or not with MET inhibitors. Elegible NSCLC patients with MET&#xD;
      exon 14 skipping mutations or MET amplification will be treated with open label orally&#xD;
      cabozantinib 60 mg/daily, cycles each 28 days. Disease evaluation will be performed every two&#xD;
      months (8 weeks). Patients will be treated with cabozantinib until disease progression,&#xD;
      unacceptable toxicity or patient refusal.Treatment will be continued until disease&#xD;
      progression, unacceptable toxicity or patient refusal. Treatment beyond disease progression&#xD;
      is allowed if considered appropriate by the investigator.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date type="Actual">September 21, 2018</start_date>
  <completion_date type="Anticipated">September 2020</completion_date>
  <primary_completion_date type="Anticipated">September 2020</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Response Rate (RR) (complete + partial responses)</measure>
    <time_frame>Up to 36 months</time_frame>
    <description>RR will be evaluated by investigators according to Response Evaluation Criteria In Solid Tumors (RECIST) version 1.1. Partial and complete responses will be confirmed following RECIST criteria 1.1. Disease evaluation will be performed every two months (8 weeks).</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Progression free survival (PFS)</measure>
    <time_frame>Up to 36 months</time_frame>
    <description>Disease evaluation will be performed every 8 weeks</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall survival (OS)</measure>
    <time_frame>Up to 36 months</time_frame>
    <description>Disease evaluation will be performed every 8 weeks</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Disease Control Rate (DCR: stable disease + partial response + complete response)</measure>
    <time_frame>Up to 36 months</time_frame>
    <description>Disease evaluation will be performed every 8 weeks</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Exploratory biomarkers</measure>
    <time_frame>Up to 36 months</time_frame>
    <description>At baseline, at the first disease evaluation and at progression of disease a blood sample will be collected for biomarkers analyses</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">25</enrollment>
  <condition>Non-Small Cell Lung Cancer</condition>
  <arm_group>
    <arm_group_label>Cabozantinib</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Elegible NSCLC patients with MET exon 14 skipping mutations or MET amplification will be treated with open label orally cabozantinib 60 mg/daily, cycles each 28 days.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cabozantinib</intervention_name>
    <description>Patients will be treated with cabozantinib 60 mg/daily (cycles each 28 days) until progression, toxicity or patient refusal.</description>
    <arm_group_label>Cabozantinib</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Citological or histological diagnosis of non-small-cell-lung cancer (NSCLC) stage III&#xD;
             B (not suitable for local treatments with curative intent) or stage IV.&#xD;
&#xD;
          2. Tissue samples available for MET analysis (archivial tissue or tissue collected at&#xD;
             study entry); patients without archival tumor tissue or refusing new biopsy at study&#xD;
             entry, are eligible if MET mutation is detected in cf-DNA&#xD;
&#xD;
          3. Presence of MET mutations (exon 14 skipping mutation ONLY) detected in tissue or&#xD;
             cf-DNA at the local lab or in the central lab or MET amplification (MET/CEP7 ratio &gt;&#xD;
             2.2) detected in the central lab ONLY.&#xD;
&#xD;
          4. Measurable disease according to RECIST criteria version 1.1&#xD;
&#xD;
          5. At least 1 prior line of standard therapy (chemotherapy and/ or immunotherapy)&#xD;
&#xD;
          6. Performance status 0-1 (ECOG)&#xD;
&#xD;
          7. Age ≥18 years&#xD;
&#xD;
          8. Patients potentially fertile using adequate methods of contraception in order to avoid&#xD;
             childbearing. Contraceptive methods must be respected by male and female patients and&#xD;
             their partners during study treatment period and at least 4 months after completing&#xD;
             therapy&#xD;
&#xD;
          9. Adequate hematologic and end organ function, defined by the following laboratory&#xD;
             results obtained within 14 days prior to enrollment:&#xD;
&#xD;
               1. ANC ≥ 1500 cells/μL without granulocyte colony-stimulating factor support&#xD;
&#xD;
               2. Platelet count ≥ 100,000/μL without transfusion&#xD;
&#xD;
               3. Hemoglobin ≥ 9.0 g/dL Patients may be transfused to meet this criterion&#xD;
&#xD;
               4. AST, ALT, and alkaline phosphatase ≤ 2.5 × ULN, with the following exceptions:&#xD;
&#xD;
                    -  Patients with documented liver metastases: AST and/or ALT ≤ 5 × ULN&#xD;
&#xD;
                    -  Patients with documented liver or bone metastases: alkaline phosphatase ≤ 5&#xD;
                       × ULN.&#xD;
&#xD;
               5. Serum bilirubin ≤ 1.25 × ULN&#xD;
&#xD;
               6. Patients with known Gilbert disease who have serum bilirubin level ≤ 3 × ULN may&#xD;
                  be enrolled&#xD;
&#xD;
               7. Calculated creatinine clearance (CRCL) ≥ 45 mL/min or calculated CRCL must be ≥&#xD;
                  60 mL/min&#xD;
&#xD;
         10. Patient compliance to the study procedure&#xD;
&#xD;
         11. Written informed consent&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Tissue sample not available in patients without MET exon 14 skipping mutation detected&#xD;
             in cf-DNA&#xD;
&#xD;
          2. No possibility to assess MET status&#xD;
&#xD;
          3. Absence of any measurable disease according to RECIST criteria&#xD;
&#xD;
          4. Co-existence of driver events, including EGFR mutations, KRAS mutations, ALK&#xD;
             rearrangements or ROS-1 rearrangements&#xD;
&#xD;
          5. No prior therapy&#xD;
&#xD;
          6. Concomitant chemotherapy or immunotherapy or radiotherapy&#xD;
&#xD;
          7. Symptomatic brain metastasis&#xD;
&#xD;
          8. Uncontrolled significant inter-current or recent illness, including cardio-vascular&#xD;
             disorders and gastro-intestinal disorders&#xD;
&#xD;
          9. Major surgery within 2 months before first dose of study treatment&#xD;
&#xD;
         10. Concomitant anti-coagulation with oral anti-coagulants or plated inhibitors&#xD;
&#xD;
         11. History of significant bleeding, trachea-bronchial tree/major blood vessels invading&#xD;
             tumors, cavity pulmonary lesions and GI disorders associated with a risk of&#xD;
             perforation or fistula formation&#xD;
&#xD;
         12. Diagnosis of another cancer in the last 3 years, except for in situ carcinoma of&#xD;
             cervix, breast and bladder or skin carcinoma (squamous or basalioid)&#xD;
&#xD;
         13. Pregnancy or breastfeeding&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Federico Cappuzzo</last_name>
    <role>Principal Investigator</role>
    <affiliation>AUSL Romagna- P.O. di Ravenna</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Federico Cappuzzo</last_name>
    <phone>0544285206</phone>
    <email>f.cappuzzo@googlemail.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Lorenza Landi</last_name>
    <email>landi.lorenza@gmail.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>A.O. &quot;S.Giuseppe Moscati&quot;</name>
      <address>
        <city>Avellino</city>
        <state>AV</state>
        <zip>83100</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Cesare Gridelli</last_name>
      <phone>0825-203945</phone>
      <email>cgridelli@libero.it</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>IRCCS Oncologico Giovanni Paolo II</name>
      <address>
        <city>Bari</city>
        <state>BA</state>
        <zip>70124</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>A.O.U. Careggi</name>
      <address>
        <city>Firenze</city>
        <state>FI</state>
        <zip>50134</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Francesco Di Costanzo</last_name>
      <phone>055-7947298</phone>
      <email>adicostanzo.oncmed@hotmail.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Irccs Irst</name>
      <address>
        <city>Meldola</city>
        <state>FO</state>
        <zip>47014</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Ospedale Infermi Rimini</name>
      <address>
        <city>Rimini</city>
        <state>FO</state>
        <zip>47923</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>A.O. Papardo</name>
      <address>
        <city>Messina</city>
        <state>ME</state>
        <zip>98158</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Vincenzo Adamo</last_name>
      <phone>090-3996150</phone>
      <email>vadamo@unime.it</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Istituto Europeo di Oncologia</name>
      <address>
        <city>Milano</city>
        <state>MI</state>
        <zip>20141</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Ospedale San Gerardo</name>
      <address>
        <city>Monza</city>
        <state>MI</state>
        <zip>20900</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Diego Cortinovis</last_name>
      <phone>039-2339678</phone>
      <email>d.cortinovis@asst-monza.it</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>AOU Policlinico di Modena</name>
      <address>
        <city>Modena</city>
        <state>MO</state>
        <zip>41124</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Fausto Barbieri</last_name>
      <email>barbieri.fausto@policlinico.mo.it</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Casa di Cura La Maddalena</name>
      <address>
        <city>Palermo</city>
        <state>PA</state>
        <zip>90146</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Vittorio Gebbia</last_name>
      <email>vittorio.gebbia@gmail.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Istituto Oncologico Veneto</name>
      <address>
        <city>Padova</city>
        <state>PD</state>
        <zip>35128</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Laura Bonanno</last_name>
      <email>laura.bonanno@iov.veneto.it</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>A.O. S.M. Misericordia</name>
      <address>
        <city>Perugia</city>
        <state>PG</state>
        <zip>06129</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Fausto Roila</last_name>
      <phone>075-5784211</phone>
      <email>roila.fausto@gmail.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Azienda Ospedaliero Universitaria Pisana</name>
      <address>
        <city>Pisa</city>
        <state>PI</state>
        <zip>56124</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Antonio Chella</last_name>
      <phone>050-996653</phone>
      <email>anto.kell@tiscali.it</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Azienda Ospedaliero- Universitaria di Parma</name>
      <address>
        <city>Parma</city>
        <state>PR</state>
        <zip>43126</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Marcello Tiseo</last_name>
      <phone>0521-702316</phone>
      <email>mtiseo@ao.pr.it</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>AUSL Reggio Emilia- IRCCS Arcispedale S.M. Nuova</name>
      <address>
        <city>Reggio Emilia</city>
        <state>RE</state>
        <zip>42123</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Fondazione Policlinico Gemelli</name>
      <address>
        <city>Roma</city>
        <state>RM</state>
        <zip>00168</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Emilio Bria</last_name>
      <email>emilio.bria@policlinicogemelli.it</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Istituto Nazionale Tumori Regina Elena</name>
      <address>
        <city>Roma</city>
        <state>RO</state>
        <zip>00144</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>A.O.U. S. Luigi Gonzaga</name>
      <address>
        <city>Orbassano</city>
        <state>Torino</state>
        <zip>10043</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Silvia Novello</last_name>
      <phone>011-9026978</phone>
      <email>silvia.novello@unito.it</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>AUSL della Romagna</name>
      <address>
        <city>Ravenna</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Federico Cappuzzo</last_name>
      <phone>0544285206</phone>
      <email>f.cappuzzo@googlemail.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Azienda Ospedaliero Universitaria Integrata di Verona</name>
      <address>
        <city>Verona</city>
        <zip>37134</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location_countries>
    <country>Italy</country>
  </location_countries>
  <verification_date>March 2019</verification_date>
  <study_first_submitted>March 28, 2019</study_first_submitted>
  <study_first_submitted_qc>April 8, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">April 11, 2019</study_first_posted>
  <last_update_submitted>April 8, 2019</last_update_submitted>
  <last_update_submitted_qc>April 8, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">April 11, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lung Neoplasms</mesh_term>
    <mesh_term>Carcinoma, Non-Small-Cell Lung</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

